Key Highlights

  • 4DMedical (ASX: 4DX) shares fell 4.03% to AUD 3.81 in a delayed intraday snapshot on 14 July 2026, underperforming the broader Healthcare sector.
  • No new price-sensitive company announcement was identified, with the decline occurring amid continued volatility following the stock’s significant FY2026 re-rating.
  • Regulatory and commercial milestones include US FDA clearance and Medicare reimbursement for CT:VQ, a European CE Mark and a distribution agreement with Philips.
  • Investors may now focus on the upcoming June-quarter cash flow report, customer receipts, scan volumes and progress in commercialising the company’s lung-imaging technology.

4DMedical Limited (ASX:4DX) shares came under pressure on Tuesday, 14 July 2026, as the lung-imaging technology company continued a period of significant share-price volatility.

The 4DX share price was trading 4.03% lower at AUD 3.81 in a delayed intraday market snapshot taken at approximately 11.16am AEST. The data feed was delayed by around 20 minutes, meaning the figures were not closing prices and may have changed later in the session.

The decline contrasted with the broader S&P/ASX 200 Healthcare Index, which was up 0.08% in the same snapshot.

No new price-sensitive company announcement was identified as the catalyst behind the fall. Instead, the move appeared consistent with the sharp two-way trading that has followed 4DMedical’s substantial share-price re-rating.

4DMedical Share Price Remains Volatile

4DMedical’s 4.03% decline placed the company among the larger S&P/ASX 200 decliners during Tuesday morning trade.

The movement followed an extraordinary period for the stock. Market data showed a 52-week trading range of approximately AUD 0.23 to AUD 7.55, reflecting a significant market re-rating rather than a share consolidation.

The shares peaked near AUD 7.55 in April 2026 before retreating from those highs.

With no fresh company announcement on Tuesday morning, the latest decline may reflect continued profit-taking and changing investor appetite towards higher-growth, pre-profit companies.

CT:VQ Regulatory Milestones Support the Growth Story

4DMedical develops medical imaging software designed to analyse and quantify lung function.

A central part of the company’s growth strategy is CT:VQ, technology that converts a routine non-contrast chest CT scan into quantitative ventilation and perfusion maps.

CT:VQ received US FDA 510(k) clearance in September 2025, followed by confirmation of Medicare reimbursement.

The company also secured a European CE Mark for CT:VQ in March 2026, enabling commercial expansion across the European Union.

These regulatory milestones have supported expectations for broader commercial adoption of the technology.

Philips Partnership Targets Commercial Expansion

4DMedical has also entered a North American distribution agreement with Philips to market its lung-imaging software.

The company’s half-year report cited contractual minimum revenue commitments of approximately AUD 15mn associated with the partnership.

4DMedical has also reported deployments or agreements with several major US healthcare institutions.

The company’s commercial model is largely based on software-as-a-service and per-scan revenue, meaning future growth depends on increasing the number of deployed sites and scans processed.

As at 31 December 2025, 4DMedical reported approximately 430 deployed sites globally and more than 151,000 scans processed during the December half.

4DMedical Remains a Pre-Profit Medtech Company

Despite its regulatory and commercial progress, 4DMedical remains a pre-profit business.

For the six months to 31 December 2025, the company reported operating revenue of AUD 2.85mn and operating expenditure of AUD 19.1mn.

The adjusted net loss narrowed 18% to AUD 16.2mn, while underlying software-as-a-service revenue increased 31%.

Cash stood at AUD 56.8mn at the end of December 2025. A AUD 150mn institutional placement completed in January 2026 lifted the pro forma cash position to AUD 206.2mn, before a further AUD 83mn placement announced in March 2026.

The company’s cash position provides funding capacity for commercial expansion, although investors may continue to focus on the pace at which revenue grows relative to expenditure.

What Could Influence the 4DMedical Share Price Next?

The June-quarter cash flow report is likely to be an important near-term event for investors.

The update may provide further information on customer receipts, operating cash outflows and the company’s closing cash balance.

Investors may also monitor scan volumes, growth in deployed sites, revenue generated through the Philips partnership and early commercial progress in Europe following the CT:VQ CE Mark.

Broader market conditions may also influence the share price. As a pre-profit growth company, 4DMedical can be sensitive to changes in investor risk appetite and interest-rate expectations.

Outlook for 4DMedical (ASX: 4DX)

4DMedical’s 4.03% intraday decline on 14 July extended a volatile period for one of the ASX’s most significantly re-rated healthcare stocks.

No new company-specific catalyst was identified for the fall, while the broader Healthcare sector remained relatively stable.

The company’s investment story continues to centre on the commercialisation of its lung-imaging technology following major regulatory milestones, including FDA clearance, Medicare reimbursement and a European CE Mark for CT:VQ.

However, 4DMedical remains pre-profit, making revenue growth, cash expenditure and commercial adoption important factors to monitor.

Investors may now focus on the June-quarter cash flow report, scan volumes, commercial progress under the Philips partnership and the company’s ability to convert regulatory milestones into revenue growth. The share-price figures referenced are delayed intraday data and may differ from the official closing price.